
    
      This is a non-interventional, multinational, multi-center post-authorization safety study
      (PASS), to assess the safety of sonidegib administered in routine clinical practice in
      patients with laBCC who are not amendable to curative surgery or radiation therapy. This
      study is observational in nature and does not impose a therapy protocol,
      diagnostic/therapeutic interventions or a specific visit schedule. For this study, each
      enrolled patient will be followed up for 3 years after enrollment.
    
  